Accelrys acquires QUMAS

Published: 10-Dec-2013
Regulatory Finance Digital

Adds end-to-end document and process management compliance solutions to portfolio


Accelrys has acquired Ireland-based QUMAS, a provider of Cloud-based and on-premises enterprise compliance software that supports regulatory and quality operations in life sciences and other regulated industries.

No financial details have been revealed.

Accelrys said the acquisition extends its informatics portfolio with the addition of end-to-end document and process management compliance solutions.

'As Accelrys continues to extend its research, laboratory and manufacturing informatics capabilities to deliver first-in-class scientific innovation lifecycle management (SILM) solutions, we're delighted to welcome the QUMAS team and the extensive compliance, quality and regulatory expertise they bring to our company,' said Accelrys' President and CEO Max Carnecchia. 'Integrating QUMAS solutions into the Accelrys product portfolio will provide a single-vendor SILM solution that is already in high demand for product lifecycle management into the critical compliance and quality management arena for science-based process industries.'

QUMAS has been refining the documentation of compliance with global mandates (including FDA and GxP standards) in regulated industries for 20 years. The firm provides an electronic document management application with related R&D submission and QA documentation packages. The business process management applications include CAPA (corrective action/preventive action), audit, change control, deviation, complaint and other critical process packages offering pre-defined and pre-tested software configurations addressing common compliance challenges.

Research, laboratory and manufacturing informatics applications such as the Accelrys ELN (Electronic Lab Notebook), Accelrys LIMS (Laboratory Information Management System),  Accelrys LES ( Lab Execution System) and Accelrys Discoverant for Operational Intelligence will function as data sources as well as integration points for the compliance and quality business systems managed by QUMAS.

Available as SaaS (Software as a Service), private Cloud or on-premises deployments, QUMAS compliance and quality solutions scale to thousands of users and millions of documents, while also fully supporting collaboration with third parties.

  • Companies:
  • Biovia
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Digital by design

Read more
With research productivity top of the agenda, Dennis Curran, Director of Product Management, BIOVIA, Dassault Systèmes (previously Accelrys), discusses how to modernise a laboratory in five key steps

Trending Articles

  1. Navigating regulatory challenges in pharmaceutical packaging: lessons from the past and strategies for the future To safeguard drug efficacy, maintain strict quality standards and ensure patient safety, pharmaceutical packaging is subject to a wide range of regulations around the world, reports Kun Shing Chan, Director of QA at Tjoapack
  2. Accord Healthcare bolsters UK drug manufacturing capabilities with £50m Newcastle facility The novel automated facility will allow Accord to produce therapeutics for oncological and autoimmune diseases for the UK and beyond
  3. Evotec strikes up a deal with Monacum Partners to sell its Halle API manufacturing facility The CDMO faction of Evotec will now function as DAPIN GmbH, which will continue to specialise in end-to-end chemical API development and manufacturing
  4. Asymchem Since inception in 1999, Asymchem has been positioned and structured to act as a true partner for pharmaceutical and biotech companies by offering integrated solutions across all stages of drug development and into commercialisation.
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Pharmaceutical method development and validation As analytical methods provide data crucial to ensure consumer health and safety, their validation is highly scrutinised. Dr Joanna Greenhough, R&D Scientist, <strong>Wickham Laboratories</strong>, outlines the best practices in validating methods used in pharmaceutical product testing

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Digital by design

With research productivity top of the agenda, Dennis Curran, Director of Product Management, BIOVIA, Dassault Systèmes (previously Accelrys), discusses how to modernise a laboratory in five key steps
Digital

Accelrys announces mobile multi-media lab application

Offers accurate, realtime multi-media capture at the bench for scientists
Hi Tech Manufacturing

Dassault Systemes and Accelrys to merge

Accelrys launches information management and collaboration workspace called ScienceCloud
You need to be a subscriber to read this article.
Click here to find out more.
Digital

Working smarter with predictive science

Optimising a molecular lead series is a critical step in transitioning initial hit compounds from screening into potent, selective and bioavailable agents suitable for progression to preclinical development and eventual consideration as candidate drugs. Advanced modelling and simulation solutions for both small molecule and macromolecule-based drug design can help to investigate and test hypotheses <i>in silico</i> prior to costly experimentation, thus reducing the time and expense involved in bringing new drugs to market
Digital

Accelrys expands process management and compliance suite

With the addition of a Laboratory Information Management System (LIMS)
Manufacturing

AstraZeneca invests $3.5bn into its US pharmaceutical research and manufacturing capabilities

The company will expand its biologics manufacturing, as well as its speciality manufacturing and cell therapy production capacity, while also extending its pharmaceutical research and development capabilities through this investment
Regulatory

Autolus Therapeutics' CAR-T therapy, Aucatzyl, bags FDA approval for ALL

Aucatzyl (obecabtagene autoleucel) is the first CAR-T therapy to receive FDA approval with no risk evaluation mitigation strategy requirement
Subscribe now